Smooth muscle cells (SMCs) in the rat carotid artery leave the quiescent state and proliferate after balloon catheter injury. The precise signals responsible for this SMC mitogenesis need to be elucidated. Although platelet-derived growth factor (PDGF), a potent SMC mitogen, is released from activated platelets, damaged endothelium, and macrophages, it cannot be solely responsible for this proliferation. In search of other SMC growth factors, we have examined several proteins of the coagulation cascade. At nanomolar concentrations, factors X, Xa, and protein S promote cultured rat aortic SMC mitosis. In contrast, factor IX is only weakly mitogenic, whereas factor VII and protein C fail to stimulate SMC division. Protein S, the most mitogenic of these coagulation cascade factors, stimulates DNA synthesis in cultured SMCs with a time course similar to that of PDGF-AA and without the delay observed for transforming growth factor .3. Antistasin and tick anticoagulant peptide, two specific factor Xa inhibitors, inhibit SMC mitogenesis due to Xa and protein S. Coagulation factors that possess mitogenic activity may contribute to intimal SMC proliferation after vascular injury as a result of angioplasty or vascular compromise during atherogenesis.
Our knowledge of intimal smooth muscle cell (SMC) proliferation in atherosclerosis derives from studies with animal models in which hyperlipidemic, fat-fed, or balloon-injured animals were used (1) (2) (3) (4) . SMC replication is well documented in these models, an extensive list of cell types has been postulated to provide the mitogenic signal, and based on these studies several theories of atherogenesis in humans have been advanced (5) (6) (7) (8) (9) (10) . During the early stages of atherogenesis, macrophages that adhere and infiltrate vascular endothelium are good candidates for such growth factor production as platelet-derived growth factor (PDGF) and interleukin 1 (11) (12) (13) (14) . Platelets, however, probably do not initiate SMC proliferation but contribute to lesion growth through the release of PDGF, epidermal growth factor (EGF), and other mitogens (15) (16) (17) (18) . Based on in situ hybridization and immunohistochemical studies of endothelial cells and SMCs underlying regions of intimal thickening, these cells can produce PDGF, fibroblast growth factor (FGF), and other molecules capable of stimulating . The primary cause of arterial intimal SMC hyperplasia during atherogenesis and the regulation of this growth factor production in vivo, however, are unknown.
Vascular endothelial alterations may be inexorably linked with SMC proliferation via the failure of endothelial cell barrier function due to denudation or to a reduction of homotypic endothelial cell adhesion and an increase in adhesivity for macrophages and platelets (24, 25) . When the endothelium is damaged, cell components of the vascular wall are exposed to circulating plasma proteins or products resulting from activation of the coagulation cascade. Although PDGF released from activated platelets has for some time now been proposed to play a leading role as a SMC mitogen, studies with PDGF neutralizing antibodies can only attribute 20o of the mitogenic activity in rat serum to PDGF (26) . Also, Bowen-Pope et al. (27) found that rat serum, which contains 16 times less PDGF than mouse serum, is equipotent as a SMC mitogen. Collectively, these experiments strongly suggest that other mitogens are present in rat sera if not in the plasma itself.
In search of other SMC mitogens present in plasma, we discovered that some proteins of the coagulation cascade, containing EGF-like domains (28) (29) (30) (31) , stimulate cultured rat aortic SMCs to divide. They are mitogenic at nanomolar concentrations, which are well within the range of physiological circulating levels of these proteins. Except for protein S, they are all proteases in their activated forms. In addition, we investigated several agents that can inhibit this coagulation factor-mediated SMC mitogenesis. Intimal SMC hyperplasia is the primary cause of vascular reocclusion and restenosis after angioplasty (32) (33) (34) (35) (36) . If these coagulation factors serve as SMC mitogens in vivo, they could contribute to the high rate arterial restenosis following angioplasty (32) (33) (34) (35) (36) SMC Cultures. Primary SMC cultures were prepared from the thoracic and abdominal aorta of 2-to 3-month-old Wistar rats essentially by the procedure of Reilly (37) . After as much fat and adherent adventitia as possible was removed with scissors and forceps, the tissue was finely minced, enzymatically dissociated by successive 370C incubations with Hanks' buffered salt solution containing collagenase (0.5 mg/ml for 15 min; Sigma), elastase (0.125 mg/ml for 30 min; Sigma), and collagenase (60 min). The dissociated cells had a spindleshaped morphology. They were grown in 10%1 fetal bovine serum/Dulbecco's modified Eagle's medium (DMEM) with antibiotics. At confluency, they exhibit extensive overlapping. Using a mAb to a-actin (Sigma), 70-90%o (preparation dependent) of these confluent cells stained positive for this SMC marker. After 10 days in culture, the cells were dissociated with trypsin-EDTA, split 1:10, and subcultured in the medium described above. At confluency, the cells were transferred to 0.1% bovine serum albumin (BSA)/DMEM for 24 hr before they were used for assay. All SMCs used in these studies were from passages 1-4. A simian virus 40 transformed SMC line (37) was provided by C. F. Reilly min, dissolved with 0.25 M NaOH (0.4 ml) incubated at 370C for 60 min, and mixed with 5 ml of Ecolume (ICN); their radioactivity was determined in a scintillation counter. Assays for each experiment were in triplicate.
Statistics. Error bars represent the SEM (n = 6 or more experiments).
RESULTS AND DISCUSSION Cultured rat aortic SMCs (passages 1-4) were treated with one of the following coagulation factors: factor X (5-50 nM), Xa (1-50 nM), IX (10-50 nM), VII (10-50 nM), protein C (20-60 nM), a-thrombin (1-50 nM), or protein S (10-50 nM). These proteins share several conserved domains; among them are variable numbers of EGF-like repeats (28, 29 (mAb4l) to epitopes of the third and fourth EGF-like domains of HPS (38) abolished its mitogenic activity (Fig. lb) protein S (10 nM), factor Xa (10 nM), and PDGF-AA (10 ng/ml) stimulated SMCs reached a maximum at =18 hr of incubation, TGF-f3 (0.1 ng/ml) stimulated SMCs were only starting to show some incorporation at this time point (Fig. 2) . This outcome suggests that protein S and factor Xa either act directly on SMCs without the induction of transcription of a growth factor gene (e.g., PDGF), which delays the onset of the mitogenic response, or they cause a release of a growth factor (e.g., basic FGF) from a cell-surface pool (42) .
Because in human plasma, 40% of protein S occurs in free form and 60%o occurs as a C4b-binding protein complex (43), we assayed the mitogenic activity of protein S, which contained a significant fraction of protein S C4b-binding protein complex, and found no apparent difference in mitogenic activity between the free and complex-containing forms (43) . Factor IX is only weakly mitogenic, whereas factor VII and protein C were inactive in the SMC assay. SMC division stimulated by these coagulation factors is obtained with concentrations below human plasma levels (29) for factor X (178 nM), factor IX (89 nM), and protein S (278 nM). In vivo, compromise of the endothelial cell barrier could permit sufficient amounts of these proteins to reach SMCs to stimulate them to divide.
From one SMC primary culture preparation to another, we observed some degree of variation in the mitogenic response obtained with a given concentration of coagulation factor. The percentage of cells that immunostained positive for a-actin, a resting state SMC marker, also varied (70-90%) with each preparation. Despite some quantitative differences H-Thxmi mn1 in mcor)orati(on. Cprn11 X 1i(- 4   FIG. 3 . Inhibition of factor Xa-mediated SMC mitogenic activity by specific factor Xa inhibitors. Details of rat SMC cultures are described in Fig. 1 . At confluency, cells were washed twice with DMEM and incubated at 37°C for 24 hr in 0.1% BSA/DMEM containing 10 nM BfXa (Boehringer Mannheim) alone or in combination with recombinant ATS or TAP. Whether ATS or TAP was added after factor Xa or was preincubated with factor Xa and added to the SMC cultures, the results were the same. At the end of the 24-hr incubation, [3H]thymidine incorporation into DNA was monitored and SMC mitogenic activity was accessed as described in Fig.  1 . Vertical line at the top of each bar represents the SEM (n = 6 or more experiments); where no bar is present, <3 experiments were performed.
observed for DNA synthesis for disparate SMC preparations, a consistent mitogenic result is obtained for several of the coagulation factors.
To rule out that a contaminant in the coagulation factor preparations was the SMC mitogen, affinity-purified rabbit antibody to HfX was used to deplete factor X preparations before assay with SMCs. No mitogenic activity remained. Since the coagulation factors used in this study are purified from bovine or human plasma, a minor contaminant that is mitogenic for SMCs but not fibroblasts cannot be completely excluded. In the case of protein S, however, this possibility appears to be less likely since a mAb (mAb4l) to epitopes of the third and fourth EGF-like domain of HPS is able to neutralize the mitogenic effect.
Also, two specific factor Xa inhibitors, ATS (44) and TAP (45) , were tested to determine whether they could inhibit the coagulation factor-mediated SMC mitogenic response. At nanomolar concentrations, which abolish factor Xa-mediated coagulation, recombinant ATS and TAP inhibit the SMC mitogenic activity of BfXa (Fig. 3) . By themselves, ATS and TAP have no effect on SMC cell division. Surprisingly, ATS and TAP abolish the SMC mitogenic activity of purified protein S but do not affect the factor X-mediated activity (Fig. 4) the endothelial cell thrombin receptor, which exhibits a proteolytic mechanism of receptor activation (46) . Factor X, however, could interact with another receptor or could activate the same receptor simply through binding.
Protein S, which is not itself a protease or a precursor but a cofactor for protein C, may activate another SMC receptor through an interaction that is blocked by ATS or TAP. Despite considerable sequence similarities between these coagulation factors (28) , not all of them are mitogenic, which suggests that the presence of an EGF-like domain alone does not confer activity. By virtue of the fact that protein S and factor Xa stimulate DNA synthesis with a time course that more closely parallels that of PDGF-AA than TGF-,f, a direct mitogenic mechanism is favored. The SMC receptor(s) involved and mechanisms for mitogenic signal transduction remain to be determined. If the endothelial cell barrier in vivo is altered, the coagulation factor-mediated SMC mitogenesis that we observed in vitro could contribute significantly to intimal SMC proliferation. Fibrinopeptide B, a product of clotting cascade activation, appears to be a chemotactic agent for macrophages (47) . Their transvascular migration during the early phases of atherosclerotic lesion formation increases the permeability ofthe endothelium to the clotting factors. Exposure of underlying SMCs to protein S may be sufficient to stimulate cell division and lead to hyperplasia. In addition, factor Xa, which promotes mitogen release from endothelial cells (48) , may alter the junctional properties of these cells. Angioplasty treatment for vascular occlusion denudes arteries of endothelium and exposes SMCs to plasma proteins. Within 6 months of this treatment, 40% of patients have restenosis, which is attributed primarily to intimal SMC hyperplasia (32) (33) (34) (35) (36) .
Experiments to determine whether these coagulation factors contribute to the process remain to be done. Confirmation that coagulation factors (e.g., protein S) contribute to intimal SMC proliferation may pave the way for therapeutic use of inhibitors such as ATS or TAP as a means of preventing restenosis after balloon angioplasty.
